CPC A61K 31/198 (2013.01) [A23K 20/142 (2016.05); A23K 50/50 (2016.05); A61K 31/167 (2013.01); A61K 31/205 (2013.01); A61K 31/223 (2013.01); A61K 31/27 (2013.01); A61K 31/341 (2013.01); A61K 31/381 (2013.01); A61K 31/683 (2013.01); A61K 38/02 (2013.01); A61K 38/05 (2013.01); A61K 38/21 (2013.01); A61K 45/06 (2013.01); A61P 21/00 (2018.01); A61P 29/00 (2018.01); A61P 31/18 (2018.01); A61P 39/00 (2018.01)] | 9 Claims |
1. A method of treating an individual for a medical condition or physical state, the method comprising providing to the individual an effective amount of a composition comprising glycine or a functional derivative thereof and N-acetylcysteine, wherein the medical condition or physical state is selected from the group consisting of:
muscle loss;
deleterious effects of weightlessness;
osteoporosis;
polycystic ovary syndrome (PCOS);
coronary artery disease;
myocardial damage after stress;
insufficient immunity following vaccination;
ototoxicity;
dizziness; and
a combination thereof.
|